HRP20140512T1 - Humana antitijela s visokim afinitetom za humani il-4 receptor - Google Patents

Humana antitijela s visokim afinitetom za humani il-4 receptor Download PDF

Info

Publication number
HRP20140512T1
HRP20140512T1 HRP20140512TT HRP20140512T HRP20140512T1 HR P20140512 T1 HRP20140512 T1 HR P20140512T1 HR P20140512T T HRP20140512T T HR P20140512TT HR P20140512 T HRP20140512 T HR P20140512T HR P20140512 T1 HRP20140512 T1 HR P20140512T1
Authority
HR
Croatia
Prior art keywords
disease
antibody
antigen
fragment
accordance
Prior art date
Application number
HRP20140512TT
Other languages
English (en)
Croatian (hr)
Inventor
Sean Stevens
Tammy T. Huang
Joel H. Martin
Jeanette L. Fairhurst
Ashique Rafique
Marcela Torres
Kevin J. Pobursky
Raymond W. Leidich
Joan A. Windsor
Warren R. Mikulka
Diana M. Ahrens
Ergang Shi
Nicholas J. Papadopoulos
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of HRP20140512T1 publication Critical patent/HRP20140512T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
HRP20140512TT 2006-10-02 2007-10-02 Humana antitijela s visokim afinitetom za humani il-4 receptor HRP20140512T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84869406P 2006-10-02 2006-10-02
US95773807P 2007-08-24 2007-08-24
PCT/US2007/021210 WO2008054606A2 (en) 2006-10-02 2007-10-02 High affinity human antibodies to human il-4 receptor

Publications (1)

Publication Number Publication Date
HRP20140512T1 true HRP20140512T1 (hr) 2014-07-04

Family

ID=39344836

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20140512TT HRP20140512T1 (hr) 2006-10-02 2007-10-02 Humana antitijela s visokim afinitetom za humani il-4 receptor
HRP20210408TT HRP20210408T1 (hr) 2006-10-02 2021-03-10 Ljudska antitijela s visokim afinitetom prema receptoru ljudskog il-4

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20210408TT HRP20210408T1 (hr) 2006-10-02 2021-03-10 Ljudska antitijela s visokim afinitetom prema receptoru ljudskog il-4

Country Status (34)

Country Link
US (4) US7605237B2 (enExample)
EP (3) EP2069403B1 (enExample)
JP (1) JP2010505418A (enExample)
KR (1) KR101474227B1 (enExample)
CN (1) CN101522716B (enExample)
AU (1) AU2007314522C9 (enExample)
BR (1) BRPI0719953B8 (enExample)
CA (1) CA2664343C (enExample)
CO (1) CO6160305A2 (enExample)
CR (1) CR10689A (enExample)
CY (1) CY1115551T1 (enExample)
DK (2) DK2069403T3 (enExample)
DO (1) DOP2009000058A (enExample)
ES (2) ES2859825T3 (enExample)
HR (2) HRP20140512T1 (enExample)
HU (1) HUE054090T2 (enExample)
IL (1) IL197479A (enExample)
LT (1) LT2769992T (enExample)
MA (1) MA31138B1 (enExample)
ME (1) ME00616B (enExample)
MX (1) MX2009003393A (enExample)
MY (1) MY149079A (enExample)
NI (1) NI200900041A (enExample)
NO (1) NO347180B1 (enExample)
NZ (1) NZ576040A (enExample)
PL (2) PL2769992T3 (enExample)
PT (2) PT2769992T (enExample)
RS (2) RS61650B1 (enExample)
RU (1) RU2445318C2 (enExample)
SI (2) SI2769992T1 (enExample)
TN (1) TN2009000110A1 (enExample)
UA (1) UA98943C2 (enExample)
WO (1) WO2008054606A2 (enExample)
ZA (1) ZA200901617B (enExample)

Families Citing this family (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
PT2314629E (pt) 2002-07-18 2014-01-22 Merus B V Produção recombinante de misturas de anticorpos
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
WO2009081201A2 (en) * 2007-12-21 2009-07-02 Medimmune Limited BINDING MEMBERS FOR INTERLEUKIN-4 RECEPTOR ALPHA (IL-4Rα) - 173
HUE057994T2 (hu) 2008-06-27 2022-06-28 Merus Nv Antitesttermelõ, transzgenikus, egérfélékhez tartozó állat
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
EP2313433A2 (en) * 2008-07-25 2011-04-27 Institute for Research in Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
AU2014216019B2 (en) * 2008-10-29 2016-04-21 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to Human IL-4 receptor
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
PT2564695E (pt) * 2009-07-08 2015-06-03 Kymab Ltd Modelos animais e moléculas terapêuticas
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
CA2789154C (en) 2010-02-08 2024-06-11 Regeneron Pharmaceuticals, Inc. Common light chain mouse
ME03386B (me) 2010-06-22 2020-01-20 Regeneron Pharma Hibridni laki lanac imunoglobulina koji ispoljavaju miševi
RU2612903C2 (ru) 2010-08-02 2017-03-13 Ридженерон Фармасьютикалз, Инк. Мыши, у которых вырабатываются связывающие белки, содержащие vl-домены
SG189220A1 (en) 2010-10-06 2013-05-31 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
WO2012162561A2 (en) 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
CN102830228B (zh) * 2011-06-15 2015-01-21 格诺思博生物科技(上海)有限公司 定量分析循环肿瘤细胞的试剂及试剂盒
AR087329A1 (es) * 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
LT2731677T (lt) 2011-07-11 2018-07-10 Glenmark Pharmaceuticals S.A. Antikūnai, kurie prisiriša prie ox40, ir jų panaudojimas
LT3418300T (lt) 2011-07-18 2021-01-11 Institute For Research In Biomedicine Neutralizuojantys antikūnai prieš gripo virusą a ir jų panaudojimas
RS66089B1 (sr) 2011-08-05 2024-11-29 Regeneron Pharma Humanizovani miševi univerzalnog lakog lanca
CN103930444B (zh) 2011-09-16 2020-08-04 瑞泽恩制药公司 用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法
EP3839049A3 (en) 2011-09-19 2021-10-20 Kymab Limited Antibodies, variable domains & chains tailored for human use
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
SI2793567T1 (sl) 2011-12-20 2019-05-31 Regeneron Pharmaceuticals, Inc. Humanizirane lahkoverižne miši
SG10201607727PA (en) 2012-03-16 2016-11-29 Regeneron Pharma Mice that produce antigen-binding proteins with ph-dependent binding characteristics
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
EP3348140B1 (en) 2012-03-16 2020-12-30 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified rodents for generating the same
RU2018128915A (ru) 2012-03-16 2019-02-18 Регенерон Фармасьютикалз, Инк. ОТЛИЧНЫЕ ОТ ЧЕЛОВЕКА ЖИВОТНЫЕ, ЭКСПРЕССИРУЮЩИЕ ЧУВСТВИТЕЛЬНЫЕ К рН ПОСЛЕДОВАТЕЛЬНОСТИ ИММУНОГЛОБУЛИНОВ
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
PT2838918T (pt) 2012-04-20 2019-08-23 Merus Nv Métodos e meios para a produção de moléculas heterrodiméricas do tipo ig
TWI656880B (zh) 2012-08-21 2019-04-21 法商賽諾菲生物技術公司 投與ｉｌ－４ｒ拮抗劑以治療或預防氣喘之方法
HUE039387T2 (hu) 2012-09-07 2018-12-28 Regeneron Pharma Atópiás dermatitisz kezelési módszerei egy IL-4R antagonista adagolásával
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
CN105734081A (zh) * 2013-02-20 2016-07-06 瑞泽恩制药公司 具有修饰的免疫球蛋白重链序列的非人类动物
ES2730011T3 (es) 2013-02-20 2019-11-07 Innate Pharma Un compuesto que se une específicamente a KIR3DL2 para el uso en el tratamiento de linfoma de células T periférico
WO2014144600A2 (en) 2013-03-15 2014-09-18 Viktor Roschke Multivalent and monovalent multispecific complexes and their uses
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
SI3010539T1 (sl) * 2013-06-21 2019-11-29 Regeneron Pharma Postopki za zdravljenje nazalne polipoze z administriranjem antagonista IL-4R
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
ES2993142T3 (en) 2013-10-01 2024-12-23 Kymab Ltd Animal models and therapeutic molecules
LT3052192T (lt) 2013-10-02 2020-12-10 Medimmune, Llc Neutralizuojantys antikūnai prieš gripą a ir jų naudojimas
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
CA2939572A1 (en) * 2014-02-19 2015-08-27 Jody Berry Marburg monoclonal antibodies
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
AU2015222951B2 (en) 2014-02-28 2020-06-11 Regeneron Pharmaceuticals, Inc. Methods for treating skin infection by administering an IL-4R antagonist
CN106164092A (zh) 2014-03-21 2016-11-23 瑞泽恩制药公司 表现不同结合特征的vl抗原结合蛋白
EP3895528A1 (en) 2014-03-21 2021-10-20 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
CN119161468A (zh) 2014-07-15 2024-12-20 免疫医疗有限责任公司 中和抗乙型流感抗体及其用途
WO2016023916A1 (en) 2014-08-12 2016-02-18 Kymab Limited Treatment of disease using ligand binding to targets of interest
WO2016071701A1 (en) 2014-11-07 2016-05-12 Kymab Limited Treatment of disease using ligand binding to targets of interest
WO2016077675A1 (en) 2014-11-14 2016-05-19 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
MX2017011443A (es) * 2015-03-06 2018-06-27 Sorrento Therapeutics Inc Terapeuticos de anticuerpo que se unen a jag1.
JP2018508224A (ja) 2015-03-19 2018-03-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗原を結合する軽鎖可変領域を選択する非ヒト動物
WO2016161010A2 (en) 2015-03-30 2016-10-06 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
WO2016156588A1 (en) 2015-04-02 2016-10-06 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
HRP20211510T1 (hr) 2015-06-01 2021-12-24 Medimmune, Llc Neutralizirajuće vezujuće molekule protiv influence i njihova uporaba
CN106699888B (zh) * 2015-07-28 2020-11-06 上海昀怡健康科技发展有限公司 一种pd-1抗体及其制备方法和应用
TW202440904A (zh) * 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（二）
CN106939047B (zh) 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
SG11201805001UA (en) 2016-01-13 2018-07-30 Medimmune Llc Method of treating influenza a
WO2017143270A1 (en) 2016-02-19 2017-08-24 Regeneron Pharmaceuticals, Inc. Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist
CN107474134B (zh) 2016-06-08 2021-07-27 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
CN109789196B (zh) 2016-09-01 2024-03-19 瑞泽恩制药公司 用于通过施用il-4r拮抗剂来预防或治疗变态反应的方法
KR20230006049A (ko) 2016-09-22 2023-01-10 리제너론 파아마슈티컬스, 인크. Il-4r 저해제 투여에 의한 중증 아토피 피부염의 치료 방법
WO2018075378A1 (en) * 2016-10-17 2018-04-26 Vanderbilt University Human respiratory syncytial virus antibodies and methods of use therefor
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
JP7350313B2 (ja) 2016-12-16 2023-09-26 ブルーフィン バイオメディシン， インコーポレイテッド 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法
CA3059350A1 (en) 2017-04-13 2018-10-18 Regeneron Pharmaceuticals, Inc. Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
CN107216388B (zh) * 2017-08-07 2020-05-05 广州泰诺迪生物科技有限公司 一种治疗丙型肝炎病毒药物的制备方法和用途
PT3515465T (pt) 2017-08-18 2024-03-04 Regeneron Pharma Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r
ES2969049T3 (es) 2017-10-30 2024-05-16 Sanofi Biotechnology Antagonista de IL-4R para uso en un método para tratar o prevenir el asma
CN108373505B (zh) 2018-04-20 2019-08-20 北京智仁美博生物科技有限公司 抗il-4r抗体及其用途
SG11202009371WA (en) 2018-05-13 2020-10-29 Regeneron Pharma Methods for treating atopic dermatitis by administering an il-4r inhibitor
CN110540590B (zh) 2018-05-29 2023-08-18 康诺亚生物医药科技（成都）有限公司 一种自免疫抑制物的开发和应用
KR20250151540A (ko) * 2018-07-16 2025-10-21 리제너론 파마슈티칼스 인코포레이티드 Ditra 질환의 비인간 동물 모델 및 이의 용도
EP3808774B1 (en) * 2018-08-24 2025-04-16 Jiangsu Hengrui Medicine Co., Ltd. Human il-4r binding antibody, antigen binding fragment thereof, and medical use thereof
CN113166259A (zh) 2018-11-09 2021-07-23 亚洲大学校产学协力团 对人IL-4受体α具有高亲和力的人抗体及其用途
CN110746507B (zh) 2018-12-25 2020-06-26 江苏荃信生物医药有限公司 抗人白介素4受体α单克隆抗体及其应用
US12187792B2 (en) 2019-03-06 2025-01-07 Regeneron Pharmaceuticals, Inc. IL-4/IL-13 pathway inhibitors for enhanced efficacy in treating cancer
CN121102493A (zh) 2019-03-21 2025-12-12 瑞泽恩制药公司 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合
WO2020210067A1 (en) * 2019-04-08 2020-10-15 Phanes Therapeutics, Inc. Humanized anti-dll3 chimeric antigen receptors and uses thereof
CN112010977B (zh) * 2019-05-29 2022-04-26 山东博安生物技术股份有限公司 抗白介素4受体(il-4r)的抗体及其应用
CN115175700A (zh) 2019-07-16 2022-10-11 赛诺菲生物技术公司 用于通过施用il-4r拮抗剂治疗或预防哮喘的方法
CN112279914A (zh) * 2019-07-25 2021-01-29 苏州丁孚靶点生物技术有限公司 Il4ra抗体、基因、载体、宿主细胞和il4ra拮抗剂
SG11202113312VA (en) 2019-08-05 2021-12-30 Regeneron Pharma Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist
EP4010373A1 (en) 2019-08-05 2022-06-15 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
MX2022006992A (es) 2019-12-09 2022-07-13 Sanofi Biotechnology Metodos para tratar los trastornos relacionados con il-4/il-13 identificados digitalmente.
EP3992974A1 (en) 2020-11-02 2022-05-04 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
WO2021167952A2 (en) * 2020-02-20 2021-08-26 The Feinstein Institutes For Medical Research Agonist antibodies against endoglin and uses thereof
CA3169959A1 (en) 2020-02-21 2021-08-26 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition containing anti-il-4r antibody and use thereof
CN119708230A (zh) * 2020-02-27 2025-03-28 正大天晴药业集团股份有限公司 结合il4r的抗体及其用途
KR20220158821A (ko) 2020-03-27 2022-12-01 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 아토피 피부염을 치료하기 위한 방법
AU2021251269A1 (en) * 2020-04-10 2022-11-17 Provincial Health Services Authority Binders and chimeric antigen receptors specific for interleukin-1 receptor accessory protein
CN113527485B (zh) 2020-04-17 2024-11-15 湖南麦济生物技术股份有限公司 抗人白细胞介素-4受体α抗体及其制备方法和应用
CN113549151A (zh) * 2020-04-24 2021-10-26 苏州康乃德生物医药有限公司 与人IL-4Rα中特定表位结合的抗体及其应用
JP2023527775A (ja) 2020-05-22 2023-06-30 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ－４ｒ阻害剤の投与により好酸球性食道炎を処置する方法
KR102468170B1 (ko) 2020-07-17 2022-11-17 (주)지아이이노베이션 ＩｇＥ Ｆｃ 수용체 알파서브유닛의 세포외 도메인 및 항-IL-4R 항체를 포함하는 융합단백질 및 이의 용도
KR102697769B1 (ko) 2020-09-14 2024-08-23 아주대학교산학협력단 인터루킨-4 수용체 알파 서브유닛과 인터루킨-5 수용체 알파 서브유닛에 동시에 결합하는 이중특이항체 및 이의 용도
CA3194111A1 (en) 2020-10-05 2022-04-14 Christine XU Methods for treating asthma in pediatric subjects by administering an il-4r antagonist
JP2023554557A (ja) 2020-12-22 2023-12-27 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 抗ｉｌ－４ｒ抗体又はその抗原結合断片の複合物及び医薬用途
WO2022150624A1 (en) * 2021-01-08 2022-07-14 Bristol-Myers Squibb Company Antibodies and antigen binding peptides for factor xia inhibitors and uses thereof
MX2023007945A (es) 2021-01-08 2023-09-21 Regeneron Pharma Metodos para tratar la alergia al cacahuate y mejorar la inmunoterapia especifica de alergeno del cacahuate mediante la administracion de un antagonista de il-4r.
US20230146317A1 (en) 2021-07-26 2023-05-11 Sanofi Biotechnology Methods for treating chronic spontaneous urticaria by administering an il-4r antagonist
TWI876192B (zh) * 2021-08-05 2025-03-11 美商美國禮來大藥廠 人類介白素-4受體α抗體
CA3227014A1 (en) 2021-08-23 2023-03-02 Ashish Bansal Methods for treating atopic dermatitis by administering an il-4r antagonist
WO2023025217A1 (zh) * 2021-08-26 2023-03-02 正大天晴药业集团股份有限公司 抗il4r抗体的药物组合物及其用途
CA3235380A1 (en) 2021-10-20 2023-04-27 Elizabeth Laws Methods for treating prurigo nodularis by administering an il-4r antagonist
CA3241374A1 (en) 2021-12-30 2023-07-06 Gregory GEBA Methods for attenuating atopic march by administering an il-4/il-13 antagonist
CA3248953A1 (en) 2022-01-29 2025-01-16 Jiangsu Hengrui Pharmaceuticals Co., Ltd. GLUCOCORTICOID MEDICINE CONJUGATE
EP4486778A1 (en) 2022-03-02 2025-01-08 Regeneron Pharmaceuticals, Inc. Manufacturing process for high titer antibody
IL316264A (en) 2022-05-02 2024-12-01 Regeneron Pharma Antibody formulations against interleukin-4 receptor (IL-4R)
CA3257038A1 (en) 2022-05-02 2023-11-09 Regeneron Pharmaceuticals, Inc. METHODS FOR REDUCING LIPASE ACTIVITY
CA3259540A1 (en) 2022-07-08 2024-01-11 Regeneron Pharmaceuticals, Inc. Methods for treating eosinophilic esophagitis in pediatric by administering an il-4r antagonist
CN120091829A (zh) 2022-08-29 2025-06-03 赛诺菲生物技术公司 通过施用il-4r拮抗剂治疗慢性诱导性寒冷性荨麻疹的方法
US20240141051A1 (en) 2022-11-01 2024-05-02 Regeneron Pharmaceuticals, Inc. Methods for treating hand and foot dermatitis by administering an il-4r antagonist
JP2025541690A (ja) 2022-11-23 2025-12-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ－４ｒアンタゴニストを投与することによる、骨成長を改善するための方法
TW202502819A (zh) 2023-03-22 2025-01-16 法商賽諾菲生物技術公司 藉由投予il-4r拮抗劑治療慢性阻塞性肺病(copd)之方法
CN121001741A (zh) 2023-03-27 2025-11-21 瑞泽恩制药公司 用于通过施用il-4r拮抗剂治疗嗜酸粒细胞性胃肠炎的方法
TW202529831A (zh) 2023-10-02 2025-08-01 美商再生元醫藥公司 藥物遞輸裝置安全系統
TW202535934A (zh) 2023-11-02 2025-09-16 美商再生元醫藥公司 利用應力來降低脂酶活性的方法
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods
WO2025221640A1 (en) 2024-04-15 2025-10-23 Sanofi Biotechnology Methods for treating chronic rhinosinusitis without nasal polyps by administering an il-4r antagonist
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US809A (en) 1838-06-27 Improved mode of changing the poles of electro-magnets
US7186A (en) 1850-03-19 fetchec
GB8808015D0 (en) 1988-04-06 1988-05-05 Ritter M A Chemical compounds
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
SG48760A1 (en) 1992-07-24 2003-03-18 Abgenix Inc Generation of xenogenetic antibodies
US5714146A (en) * 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
EP0604693A1 (en) * 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
ZA946875B (en) * 1993-09-07 1995-07-06 Smithkline Beecham Corp Recombinant il4 antibodies useful in treatment of il4 mediated disorders
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
WO2001092340A2 (en) 2000-05-26 2001-12-06 Immunex Corporation Use of interleukin-4 antagonists and compositions thereof
US7879328B2 (en) * 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AR037456A1 (es) * 2001-11-30 2004-11-10 Biogen Inc Anticuerpos contra proteinas quimiotacticas monocitarias
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
CA2543982C (en) 2003-11-07 2013-01-08 Immunex Corporation Antibodies that bind interleukin-4 receptor
AU2004309373A1 (en) * 2003-12-22 2005-07-14 Amgen Inc. Methods for identifying functional antibodies
DE602005006758D1 (de) * 2004-02-27 2008-06-26 Regeneron Pharma Il-4/il-13-spezifische polypetide und deren therapeutische verwendung
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
TWI307630B (en) * 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
TWI306862B (en) * 2005-01-03 2009-03-01 Hoffmann La Roche Antibodies against il-13 receptor alpha 1 and uses thereof
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor

Also Published As

Publication number Publication date
PL2069403T3 (pl) 2015-08-31
US7794717B2 (en) 2010-09-14
EP2769992A2 (en) 2014-08-27
EP2769992A3 (en) 2015-01-21
BRPI0719953B1 (pt) 2019-04-24
US20100291107A1 (en) 2010-11-18
HRP20210408T1 (hr) 2021-04-30
AU2007314522C1 (en) 2013-06-27
BRPI0719953B8 (pt) 2021-05-25
SI2069403T1 (sl) 2014-09-30
PL2769992T3 (pl) 2021-08-02
RS53340B (sr) 2014-10-31
UA98943C2 (ru) 2012-07-10
CO6160305A2 (es) 2010-05-20
DK2069403T3 (da) 2014-07-28
EP3845563A2 (en) 2021-07-07
ZA200901617B (en) 2009-12-30
CY1115551T1 (el) 2017-01-04
ES2466669T3 (es) 2014-06-10
NI200900041A (es) 2011-10-17
WO2008054606A2 (en) 2008-05-08
US20100021476A1 (en) 2010-01-28
ES2859825T3 (es) 2021-10-04
EP2069403B1 (en) 2014-05-07
LT2769992T (lt) 2021-04-12
NO20091758L (no) 2009-05-04
AU2007314522A1 (en) 2008-05-08
NZ576040A (en) 2011-06-30
MA31138B1 (fr) 2010-02-01
PT2069403E (pt) 2014-07-18
PT2769992T (pt) 2021-03-11
NO347180B1 (no) 2023-06-19
JP2010505418A (ja) 2010-02-25
EP2769992B1 (en) 2020-12-30
TN2009000110A1 (en) 2010-08-19
SI2769992T1 (sl) 2021-04-30
US8092802B2 (en) 2012-01-10
WO2008054606A3 (en) 2009-02-05
HK1131790A1 (en) 2010-02-05
CN101522716B (zh) 2013-03-20
EP2069403A2 (en) 2009-06-17
MEP11109A (en) 2011-12-20
US20120135010A1 (en) 2012-05-31
CA2664343C (en) 2016-04-26
ME00616B (me) 2011-12-20
US7605237B2 (en) 2009-10-20
US20080160035A1 (en) 2008-07-03
IL197479A0 (en) 2011-08-01
MX2009003393A (es) 2009-05-11
AU2007314522B8 (en) 2013-04-11
RU2445318C2 (ru) 2012-03-20
HK1200846A1 (en) 2015-08-14
MY149079A (en) 2013-07-15
AU2007314522A8 (en) 2013-04-11
AU2007314522A2 (en) 2009-07-02
AU2007314522B2 (en) 2013-02-21
BRPI0719953A2 (pt) 2014-04-29
HUE054090T2 (hu) 2021-08-30
RS61650B1 (sr) 2021-04-29
KR20090088865A (ko) 2009-08-20
AU2007314522C9 (en) 2013-08-01
US8338135B2 (en) 2012-12-25
CR10689A (es) 2009-06-24
DOP2009000058A (es) 2009-04-30
CA2664343A1 (en) 2008-05-08
DK2769992T3 (da) 2021-03-22
CN101522716A (zh) 2009-09-02
RU2009116608A (ru) 2010-11-10
EP3845563A3 (en) 2021-11-24
KR101474227B1 (ko) 2014-12-18
IL197479A (en) 2014-03-31

Similar Documents

Publication Publication Date Title
HRP20140512T1 (hr) Humana antitijela s visokim afinitetom za humani il-4 receptor
JP2010505418A5 (enExample)
US20250154241A1 (en) Antigen binding proteins capable of binding thymic stromal lymphopoietin
JP6883591B2 (ja) 抗ヒトインターロイキン−１７ａモノクローナル抗体、その製造方法及び使用
RU2011120194A (ru) Человеческие антитела с высокой аффинностью к рецепторам il-4 человека
CN108409860B (zh) 抗人白细胞介素-4受体α单克隆抗体、其制备方法和应用
AU2024200493A1 (en) ANTI-IL-23p19 ANTIBODY AND USE THEREOF
JP2007537132A (ja) インターロイキン−２２に対する抗体およびその使用
CN117106084B (zh) 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
JP2016210782A (ja) ヒト抗体及びタンパク質
JP2007500132A (ja) Ｌｄｃａｍのアンタゴニストおよびアゴニスト、並びにその使用法
NZ722445A (en) Antibodies directed against interleukin-33 (il-33)
TW201117824A (en) Use of IL-17 receptor a antigen binding proteins
KR20180048571A (ko) 항체 에피토프
JP2012524524A5 (enExample)
CN115433275A (zh) 抗胸腺基质淋巴细胞生成素（tslp）抗体及其用途
CN109942706A (zh) 结合人il-5的单克隆抗体、其制备方法和用途
KR20150119357A (ko) 우레아 유도체 및 이의 지방산 결합 단백질(fabp) 억제제로서의 용도
JP2025041615A (ja) 抗ｔｎｆ抗体組成物を産生するための産生方法
US12258392B2 (en) Anti-IL-25 antibodies and use thereof
WO2008112543A2 (en) Rat, rabbit, and cynomolgus monkey il-21 and il-22 nucleotide and polypeptide sequences
WO2009003096A2 (en) Il-17 mutein proteins, antibodies, compositions, methods and uses
CN114456267A (zh) 一种抗cd73人源化单克隆抗体及其应用
CN120192410A (zh) 一种犬源化的犬il-31的单克隆抗体及其应用
CN105777905A (zh) 一种全人源抗TNF-α单克隆抗体及其应用